Jyh-Jou Chen

Chi Mei Medical Center — Taiwan

Medicine · Health Sciences

15h-index718citations63works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(34), Liver Disease Diagnosis and Treatment(34), Hepatitis B Virus Studies(27), Liver Disease and Transplantation(6), Helicobacter pylori-related gastroenterology studies(4)

Publications61 total

Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
Journal of the Formosan Medical Association·2025Open Access
Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
Infectious Diseases and Therapy·2025Open Access
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
Clinical and Molecular Hepatology·2024· 1 citedOpen Access
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Clinical and Molecular Hepatology·2024· 13 citedOpen Access
Genetic history of hepatitis C virus genotype 6 in Taiwan
Journal of the Formosan Medical Association·2023· 3 citedOpen Access
Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switchingto tenofovir alafenamide in chronic hepatitis B patients
Journal of Hepatology·2023
Effect of Tenofovir and Entecavir on occurrence of hepatocellular carcinoma depends on duration of antiviral treatment and hierarchical PAGE-B risk score
Journal of Hepatology·2023
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Hepatology International·2023· 20 cited
Bile Duct Stone Size May Influence the Efficacy of Endoscopic Sphincterotomy With or Without Large-Balloon Dilation: A Meta-Analysis
Journal of Laparoendoscopic & Advanced Surgical Techniques·2022· 3 cited
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
Research Square (Research Square)·2022· 5 citedOpen Access
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Journal of Hepatology·2022· 69 cited
Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide-an interim analysis
Journal of Hepatology·2022
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
Journal of the Formosan Medical Association·2022· 5 citedOpen Access
Bile duct stone size may influence the efficacy of endoscopic sphincterotomy with or without large-balloon dilation - A meta-analysis
Research Square (Research Square)·2022Open Access
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study.
PubMed·2022· 6 citedOpen Access
Food Away From Home and Self-Perceived Gastrointestinal Health
Frontiers in Nutrition·2021· 2 citedOpen Access
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
Clinical and Molecular Hepatology·2021· 21 citedOpen Access
Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution
Viruses·2021· 3 citedOpen Access
Geographic Variation of Indigenous Hepatitis C Virus Subtypes 6g and 6w in an Endemic Area of Southern Taiwan
Research Square (Research Square)·2021Open Access
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
2021Open Access
page 1 of 4Next →

Frequent Co-authors

Chun‐Jen Liu(16), Chi-Yi Chen(15), Hsing‐Tao Kuo(15), Pei‐Lun Lee(15), Kuo‐Chih Tseng(14), Cheng‐Yuan Peng(12), Ming‐Lung Yu(12), Gin‐Ho Lo(11), Jia‐Horng Kao(10), Hsueh‐Chou Lai(9), Chen‐Hua Liu(9), Wei‐Wen Su(9), Pin‐Nan Cheng(9), Jee‐Fu Huang(9), Chia‐Yen Dai(9), Hung‐Da Tung(9), Wan‐Long Chuang(8), Ming‐Lun Yeh(8), Rong‐Nan Chien(7), Chi‐Ming Tai(7)